Efficacy and Safety of Ravidasvir Plus Sofosbuvir in Chronic Hepatitis C Infected Subjects Without Cirrhosis or with Compensated Cirrhosis: Interim Analysis Results of a Two-Stage, Open-Label, Multicentre, Phase 2/3 Trial
Isabelle Andrieux‐Meyer(Drugs for Neglected Diseases Initiative), Shahnaz Murad(Institute for Medical Research), Tim R. Cressey, François Bompart(Drugs for Neglected Diseases Initiative), Caroline Menétrey(Drugs for Neglected Diseases Initiative), Sabine Yerly(Unknown), Muhammad Radzi Abu Hassan(Hospital Sultanah Bahiyah), Anchalee Avihingsanon(Chulalongkorn University), Sombat Thanprasertsuk(Ministry of Public Health), Soek-Siam Tan(Hospital Selayang), Hajjah Rosaida Hj Mohd Said(KPJ Ampang Puteri Specialist Hospital), Nicole Ngo‐Giang‐Huong(Chiang Mai University), Alistair Swanson(Drugs for Neglected Diseases Initiative), Kanawee Thetket(Nakornping Hospital), Satawat Thongsawat(Maharaj Nakorn Chiang Mai Hospital), Wah‐Kheong Chan(University of Malaya), Bernard Pecould(Drugs for Neglected Diseases Initiative), Nicolas Salvadori(Chiang Mai University), Vishal Goyal(Chandigarh University), Suresh Kumar(Hospital Sungai Buloh), Haniza Omar(Hospital Selayang), Sasikala Siva(Drugs for Neglected Diseases Initiative), François Simon, Hoi‐Poh Tee(Hospital Tengku Ampuan Afzan), Suparat Khemnark(Bamrasnaradura Infectious Diseases Institute)
Cited by 0
Related Papers
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
|The Lancet|2022|15.8k
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
|Hepatology International|2020|295
Global burden of metabolic diseases, 1990–2021
|Metabolism|2024|294
Safety of efavirenz in the first trimester of pregnancy
|AIDS|2014|274